Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Progressive Familial Intrahepatic Cholestasis (PFIC): full-pipeline trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Progressive Familial Intrahepatic Cholestasis (PFIC): 2 US clinical trials tracked, none currently recruiting.
Progressive Familial Intrahepatic Cholestasis (PFIC) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Mirum Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition progressive-familial-intrahepatic-cholestasis-pfic
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Progressive Familial Intrahepatic Cholestasis (PFIC) has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Progressive Familial Intrahepatic Cholestasis (PFIC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Progressive Familial Intrahepatic Cholestasis (PFIC) is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
Mirum Pharmaceuticals
NCT04185363
Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis
Mirum Pharmaceuticals
NCT02057718
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Progressive Familial Intrahepatic Cholestasis (PFIC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Progressive Familial Intrahepatic Cholestasis (PFIC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Progressive Familial Intrahepatic Cholestasis (PFIC) page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Progressive Familial Intrahepatic Cholestasis (PFIC) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Mirum Pharmaceuticals sponsors the most Progressive Familial Intrahepatic Cholestasis (PFIC) trials on record, review their full trial history before evaluating a specific study. See Mirum Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Progressive Familial Intrahepatic Cholestasis (PFIC) condition card totals 2 registered trials; most-linked intervention LUM001 (Maralixibat); top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.